The price of generic capmatinib in Laos is revealed

Capmatinib (Capmatinib), known by the trade name Tabrecta, is a selective MET inhibitor developed by Novartis, specifically for Designed to treat patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. This drug effectively inhibits the proliferation and metastasis of tumor cells by precisely targeting the MET signaling pathway, bringing new treatment hope to front-line and previously treated patients. As an outstanding representative of precision medicine, capmatinib received breakthrough therapy certification from the U.S. Food and Drug Administration (FDA) and was successfully launched.

The core efficacy of capmatinib is reflected in the treatment of advanced or metastatic NSCLC patients with MET gene exon 14 skipping mutations. Clinical trial data show that its overall response rate (ORR) is quite impressive, especially in patients who have not received treatment, the response rate is as high as 68%. At the same time, the drug also demonstrated excellent disease control rate (DCR), opening up new treatment avenues for patients who are ineffective with traditional treatments.

However, capmatinib is not yet available in mainland China, and patients must obtain it through legal overseas medical channels or international purchasing agents. Novartis' original drugs are expensive, with a box often costing tens of thousands of yuan, which puts considerable financial pressure on many patients. As a result, generic drugs have become an affordable option for many patients.

It is reported that the price of generic capmatinib produced in Laos is relatively affordable, with a box costing about 3,000 yuan. Although the price is low, the ingredients of Lao generic drugs are highly consistent with the original drugs and the efficacy is equivalent, so they are favored by patients in developing countries. When choosing generic drugs, patients are advised to purchase them through formal channels to ensure the quality and safety of the drugs.

No matter whether patients choose original drugs or generic drugs, they must undergo genetic testing to confirm the MET exons before using capmatinib.14The existence of jump mutations. During treatment, patients should be followed up regularly and monitored for adverse drug reactions. Because capmatinib may cause side effects such as nausea, vomiting, and abnormal liver function, patients need to adjust the dose or take symptomatic treatment measures according to the doctor's recommendations.

xa0

Reference materials

Novartis official website:https://www.novartis.com